Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial-Reference-Cited by-同舟云学术

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

Published:2015-04 Issue:4 Volume:26 Page:702-708
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gruenberger T.,Bridgewater J.,Chau I.,García Alfonso P.,Rivoire M.,Mudan S.,Lasserre S.,Hermann F.,Waterkamp D.,Adam R.

Funder

F. Hoffmann-La Roche Ltd.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/4/702/16699243/mdu580.pdf

Reference24 articles.

1. LiverMetSurvey: an international registry of liver metastases of colorectal cance. www.livermetsurvey.org (updated June 2012) (22 July 2014, date last accessed).

2. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone;Ferrarotto;Clin Colorectal Cancer,2011

3. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer—an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009;Adam;Ann Oncol,2010

4. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group;Nordlinger;Eur J Cancer,2007

5. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival;Adam;Ann Surg,2004

Cited by 282 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FOLFOXIRI for First-Line Treatment of Unresectable Colorectal Cancer with Liver Metastases in a Resource-Limited Setting;2024-09-03

2. PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX01): An open label, non-comparative phase 1/2 dose escalation and expansion trial;European Journal of Surgical Oncology;2024-09

3. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC;Med;2024-09

4. Determinants of Metastatic Colorectal Cancer With Permanent Liver- Limited Disease;Clinical Colorectal Cancer;2024-09

5. Safety and efficacy of percutaneous arterial port Implantation for Hepatic Arterial Infusion Chemotherapy;European Radiology;2024-07-30